1.
Khrom M, Long M, Dube S, et al. Comprehensive association analyses of extraintestinal manifestations in inflammatory bowel disease. Gastroenterology. 2024. doi:10.1053/j.gastro.2024.02.026.
1.
Bhosle A, Bae S, Zhang Y, et al. Integrated annotation prioritizes metabolites with bioactivity in inflammatory bowel disease. Molecular systems biology. 2024. doi:10.1038/s44320-024-00027-8.
1.
Babbe H, Sundberg TB, Tichenor M, et al. Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation. Proceedings of the National Academy of Sciences of the United States of America. 2024;121(1):e2307086120. doi:10.1073/pnas.2307086120.
1.
Williams KM, Challa PK, Lopes EW, et al. Periodontal disease is not associated with risk of inflammatory bowel disease: Results from two prospective cohort studies in the US. Alimentary pharmacology & therapeutics. 2023. doi:10.1111/apt.17732.
1.
Braun T, Sosnovski KE, Amir A, et al. Mucosal transcriptomics highlight lncRNAs implicated in ulcerative colitis, Crohn’s disease, and celiac disease. JCI insight. 2023;8(14). doi:10.1172/jci.insight.170181.
1.
Kong L, Pokatayev V, Lefkovith A, et al. The landscape of immune dysregulation in Crohn’s disease revealed through single-cell transcriptomic profiling in the ileum and colon. Immunity. 2023. doi:10.1016/j.immuni.2023.01.002.